We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$505M
AUM Growth
+$162M
(+47%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
32.79%
Top 10 Holdings %
Top 10 Hldgs %
36.69%
Holding
110
New
32
Increased
27
Reduced
17
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$19.7M |
| 2 |
Johnson & Johnson
JNJ
|
+$16.9M |
| 3 |
AMN Healthcare
AMN
|
+$14.3M |
| 4 |
Cigna
CI
|
+$14.3M |
| 5 |
ALBO
Albireo Pharma Inc
ALBO
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$8.84M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$8.57M |
| 3 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$8.51M |
| 4 |
Eli Lilly
LLY
|
+$7.54M |
| 5 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$6.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.38% |
| 2 | Consumer Staples | 0.82% |
| 3 | Financials | 0.57% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRAY
26
DELISTED
ViewRay, Inc.
VRAY
| $7.13M | 1.41% |
2,038,175
+743,385
| +57% | +$2.07M |
|
27
Orthofix Medical
OFIX
$427M
| $6.79M | 1.34% |
217,917
+26,026
| +14% | +$807K |
|
28
United Therapeutics
UTHR
$22.4B
| $5.98M | 1.18% |
59,210
-6,000
| -9% | -$658K |
|
|
SYNH
29
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $5.92M | 1.17% |
+111,285
| New | +$6.63M |
|
30
Curis
CRIS
$8.5M
| $5.79M | 1.15% |
12,375
+1,625
| +15% | +$767K |
|
31
Kodiak Sciences
KOD
$2.81B
| $5.46M | 1.08% |
92,150
+71,555
| +347% | +$3.59M |
|
|
MRSN
32
DELISTED
Mersana Therapeutics
MRSN
| $5.43M | 1.08% |
11,671
-3,200
| -22% | -$1.62M |
|
|
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5.37M | 1.06% |
71,753
-23,400
| -25% | -$1.56M |
|
|
CSII
34
DELISTED
Cardiovascular Systems, Inc.
CSII
| $4.91M | 0.97% |
+124,808
| New | +$4.03M |
|
35
Larimar Therapeutics
LRMR
$434M
| $4.56M | 0.9% |
300,591
-17,667
| -6% | -$224K |
|
|
EPIX
36
DELISTED
ESSA Pharma
EPIX
| $4.53M | 0.9% |
+656,043
| New | +$4.45M |
|
37
Elevance Health
ELV
$84.6B
| $4.31M | 0.85% |
16,031
-15,788
| -50% | -$4.25M |
|
|
CHAQ.U
38
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
| $4.22M | 0.84% |
400,000
| – | – |
|
39
Quanterix
QTRX
$179M
| $4.2M | 0.83% |
124,609
-21,298
| -15% | -$686K |
|
40
Herbalife
HLF
$1.19B
| $4.13M | 0.82% |
+88,600
| New | +$4.35M |
|
41
Viking Therapeutics
VKTX
$3.89B
| $4.13M | 0.82% |
709,780
| – | – |
|
42
Medtronic
MDT
$110B
| $4.05M | 0.8% |
+39,000
| New | +$3.92M |
|
43
Ardelyx
ARDX
$1.2B
| $3.96M | 0.78% |
754,321
+152,787
| +25% | +$918K |
|
44
Becton Dickinson
BDX
$48.6B
| $3.86M | 0.76% |
+16,987
| New | +$4.17M |
|
45
RadNet
RDNT
$5.31B
| $3.43M | 0.68% |
223,561
+88,307
| +65% | +$1.39M |
|
46
Anika Therapeutics
ANIK
$268M
| $3.33M | 0.66% |
94,102
+58,070
| +161% | +$2.1M |
|
|
AFMD
47
DELISTED
Affimed
AFMD
| $3.09M | 0.61% |
91,128
-2,187
| -2% | -$82.8K |
|
|
CYPH
48
Cypherpunk Technologies Inc
CYPH
$71.8M
| $2.88M | 0.57% |
145,200
-5,000
| -3% | -$96.5K |
|
|
LSACU
49
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
| $2.86M | 0.57% |
210,000
| – | – |
|
50
Orchestra BioMed
OBIO
$246M
| $2.75M | 0.54% |
+250,000
| New | +$2.81M |
|
Similar funds
GUB
KLI
JA
AAM
TCM
CA
SAM
ACM
Sio Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Sio Capital Management held 110 positions worth $505M, up 47% from $343M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sio Capital Management deployed $166M of net new capital in Q3 2020, opening 32 new positions and adding to 27 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 76% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $8.57M trimmed.
- Sio Capital Management's largest Q3 2020 buy was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.
- Sio Capital Management added most to HILL-ROM HOLDINGS, INC. in Q3 2020, an estimated $10.8M increase.
- Sio Capital Management's biggest Q3 2020 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.57M.
- Sio Capital Management fully exited Merck in Q3 2020, selling an estimated $8.84M.
- Sio Capital Management's ten largest holdings make up 37% of its $505M portfolio in Q3 2020.
- Sio Capital Management opened 32 new positions and closed 21 in Q3 2020.
- Sio Capital Management's portfolio value rose 47% quarter-over-quarter to $505M.
Based on Sio Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.